Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

Basit Öğe Kaydı
dc.contributor.authorInal, Ali
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKilinc, Faruk
dc.contributor.authorIsikdogan, Abdurrahman
dc.date.accessioned2024-04-24T16:18:19Z
dc.date.available2024-04-24T16:18:19Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: It has been demonstrated that there are a lot of different prognostic factors which Non-small cell lung are worthy of consideration whereas diabetes mellitus (DM) has not been clearly or consistently identified as a prognostic value in advanced non-small cell lung cancer (NSCLC). The aim Prognostic factors of this study was to investigate the prognostic significance of the characteristics of patients in advanced NSCLC. Specifically, we investigated the impact of DM for progression-free survival (PFS) and overall survival (OS) in patients receiving first-line platinum-based doublets chemotherapy. Methods: We retrospectively reviewed 442 patients with advanced NSCLC. DM and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for OS were identified as having prognostic significance: performance status (p < 0.001), stage (p < 0.001), DM (p < 0.001), liver metastasis (p = 0.02) and brain metastasis (p < 0.001). Stage, diabetes mellitus, and liver metastasis were identified as having prognostic significance for PFS. Multivariate analysis showed that poor performance status, presence of DM and advanced stage were considered independent negative prognostic factors for OS (p 0.001, p < 0.001 and p < 0.001 respectively). Furthermore, DM and stage were considered independent negative prognostic factors for PFS (p 0.005 and p 0.001 respectively). Conclusion: In conclusion, DM at the time of diagnosis was associated with the negative prognostic importance for PFS and OS in the advanced stage patients who were receiving first-line platinum-based doublets chemotherapy. In addition poor performance status and advanced stage were identified as negative prognostic factors. (c) 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.en_US
dc.identifier.doi10.1016/j.rppneu.2013.09.001
dc.identifier.endpage68en_US
dc.identifier.issn0873-2159
dc.identifier.issue2en_US
dc.identifier.pmid24210228
dc.identifier.scopus2-s2.0-84904575559
dc.identifier.scopusqualityN/A
dc.identifier.startpage62en_US
dc.identifier.urihttps://doi.org/10.1016/j.rppneu.2013.09.001
dc.identifier.urihttps://hdl.handle.net/11468/15996
dc.identifier.volume20en_US
dc.identifier.wosWOS:000334263100004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Espana Sluen_US
dc.relation.ispartofRevista Portuguesa De Pneumologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectNon-Small Cell Lungen_US
dc.subjectCanceren_US
dc.subjectPrognostic Factorsen_US
dc.titleIs diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?en_US
dc.titleIs diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu